Comparative Pharmacology
Head-to-head clinical analysis: CURRETAB versus ETHINYL ESTRADIOL ETONOGESTREL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CURRETAB versus ETHINYL ESTRADIOL ETONOGESTREL.
CURRETAB vs ETHINYL ESTRADIOL; ETONOGESTREL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Progesterone receptor agonist; induces secretory changes in endometrium, inhibits pituitary gonadotropin secretion, and has anti-estrogenic effects.
ETHINYL ESTRADIOL is an estrogen; ETONOGESTREL is a progestin. The combination suppresses gonadotropin (FSH and LH) release from the pituitary, inhibiting ovulation, thickening cervical mucus to impede sperm penetration, and altering endometrial receptivity.
5 mg orally once daily for 10 consecutive days per cycle, beginning on day 16 of the menstrual cycle.
One vaginal ring (0.120 mg etonogestrel/0.015 mg ethinyl estradiol per day) inserted vaginally and left in place for 3 weeks, followed by a 1-week ring-free period.
None Documented
None Documented
Terminal elimination half-life of medroxyprogesterone acetate (MPA) is approximately 12-17 hours (mean ~14 h) for oral administration; with intramuscular depot, half-life extends to ~6-7 weeks due to slow absorption from injection site
Ethinyl estradiol: ~13 hours (range 7-20 h); etonogestrel: ~25 hours (range 15-36 h). At steady state, elimination half-life extends to 20-30 h for etonogestrel.
Primarily renal (60-70% as metabolites, <10% unchanged); biliary/fecal (20-30%)
Urine (60-70% as metabolites, <10% unchanged), feces (20-30% via biliary elimination).
Category C
Category D/X
Progestin
Progestin